Bimatoprost Ophthalmic for Ocular Hypertension

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Ocular Hypertension+1 MoreBimatoprost Ophthalmic - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether a new glaucoma medication is as effective as the current standard medication.

Eligible Conditions
  • Ocular Hypertension
  • Glaucoma

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: up to Week12

up to Week12
Change from baseline (Day 1) to Week 2, Week 6, and Week 12 in IOP.

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Lumigan
1 of 2
T4032
1 of 2

Active Control

Experimental Treatment

500 Total Participants · 2 Treatment Groups

Primary Treatment: Bimatoprost Ophthalmic · No Placebo Group · Phase 3

T4032
Drug
Experimental Group · 1 Intervention: Bimatoprost Ophthalmic · Intervention Types: Drug
Lumigan
Drug
ActiveComparator Group · 1 Intervention: Bimatoprost Ophthalmic · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to week12

Who is running the clinical trial?

Laboratoires TheaLead Sponsor
51 Previous Clinical Trials
5,521 Total Patients Enrolled
6 Trials studying Ocular Hypertension
1,754 Patients Enrolled for Ocular Hypertension

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have open-angle glaucoma or ocular hypertension.

Who else is applying?

What state do they live in?
Pennsylvania100.0%
How old are they?
18 - 65100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%
Why did patients apply to this trial?
  • "I am 73 years old female I have catarac in my eyes I have been operete once on the eye but I can't even from distance"
How many prior treatments have patients received?
1100.0%